Recent advancements in cancer treatment have significantly improved the prognosis and longevity of patients suffering from various forms of the disease. However, colorectal cancer (CRC), particularly in its metastatic stage, remains a formidable challenger, often eluding early detection and presenting a pressing need for effective therapies that can tackle metastases without severe systemic toxicity. In a groundbreaking study published in Biomaterials, researchers from The University of Chicago have unveiled a nanotechnology-based approach that offers a beacon of hope for CRC treatment by employing nanoscale coordination polymers (NCPs) that carry and release microRNA (miRNA) to curb metastasis. The results of this study embody a major step forward in oncology and nanomedicine, presenting a promising strategy that blends precision and safety in combating colorectal liver metastases.

The Perils of Metastatic Colorectal Cancer

Colorectal cancer is among the leading causes of cancer-related deaths globally. Metastatic CRC, wherein cancer cells spread to distant organs such as the liver, presents particularly daunting prognostic implications. Conventional approaches, such as chemotherapy, often bear the burden of severe side effects due to systemic toxicity. This underpins the exigency for therapies that specifically target metastatic sites without inducing undue harm to healthy tissues.

The Role of MicroRNA in Cancer Progression and Metastasis

MicroRNAs are small non-coding RNA molecules that play crucial roles in the regulation of gene expression. Alterations in miRNA expression are frequently associated with the mechanism of cancer progression and metastasis, making them a focal point for targeted cancer therapy. The study in Biomaterials harnesses the power of miR-655-3p, a miRNA known for its ability to suppress the epithelial-to-mesenchymal transition (EMT), a biological process that is pivotal in the development and metastasis of cancer cells.

Nanoscale Coordination Polymers: A Novel Therapeutic Carrier

The innovative therapeutic strategy described in the article leverages the unique properties of NCPs. These structures consist of metal ions and organic ligands that assemble into nanoparticles, serving as protective vehicles for miRNA during circulation in the bloodstream and enabling its controlled release within tumor cells. According to the DOI: 10.1016/j.biomaterials.2019.04.028, this NCP-based system demonstrates an extraordinary capability to deliver therapeutic miRNA effectively to the sites of CRC metastases in the liver.

Methodology and Findings

The research team, led by professors Wenbin Lin and Ralph R. Weichselbaum, engineered NCPs to encapsulate miR-655-3p and tested their efficacy in mouse models of metastatic CRC. The results were striking: the NCPs homed to the liver metastases and released their payload, significantly reducing tumor growth and the invasiveness of the cancer cells. Furthermore, the treatment inhibited the EMT, cutting off a critical path by which CRC metastasizes.

Advantages and Implications

One of the paramount advantages of the NCP system is its reduced toxicity profile. Traditional chemotherapeutic agents indiscriminately attack rapidly dividing cells, often leading to debilitating side effects. In stark contrast, the targeted release of miRNA via NCPs minimizes systemic exposure and focuses the therapeutic effect where it is most needed, opening new avenues for treatment protocols that can spare patients severe side effects.

Potential for Clinical Application

While the study reflects early-stage research, the outcomes suggest vast potential for clinical applications. The pinpoint accuracy of NCPs in delivering miRNA to metastatic sites embodies the essence of personalized medicine, tailored to address the unique challenges of each patient’s disease. The technology sets the stage for treatments that could significantly extend the quality and duration of life for patients with metastatic CRC.

The Road Ahead

Before this nanotechnology can be integrated into standard clinical practice, there are several hurdles to overcome. Clinical trials will need to confirm the efficacy and safety profile observed in preclinical studies. Furthermore, scaling up the production of NCPs and ensuring their reproducibility and stability for widespread use will require substantial additional research and development.


This landmark research represents a pivotal juncture in the fight against colorectal cancer metastases. By marrying the specificity of miRNA therapy with the precision delivery capabilities of NCPs, the team at The University of Chicago has taken a significant leap forward in oncological nanomedicine. Their findings not only pave the way for more effective interventions but also portend a future where cancer treatment is defined by its precision and benignity, rather than a brute force approach.


1. Colorectal Cancer Metastasis Treatment
2. Nanoscale Coordination Polymers
3. Targeted miRNA Therapy
4. Non-Toxic Cancer Nanotechnology
5. EMT Suppression in CRC


1. Chan C., Guo N., Duan X., et al. (2019). Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer. Biomaterials, 210, 94–104. DOI: 10.1016/j.biomaterials.2019.04.028
2. Mehlen P., & Puisieux A. (2006). Metastasis: a question of life or death. Nature Reviews Cancer, 6(6), 449–458. DOI: 10.1038/nrc1886
3. Steeg P. S., & Theodorescu D. (2008). Metastasis: a therapeutic target for cancer. Nature Clinical Practice Oncology, 5(4), 206–219. DOI: 10.1038/ncponc1078
4. Reddy K. B. (2015). MicroRNA (miRNA) in cancer. Cancer Cell International, 15, 38. DOI: 10.1186/s12935-015-0185-1
5. Chen Y., Gao D. Y., & Huang L. (2015). In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Advanced Drug Delivery Reviews, 81, 128–141. DOI: 10.1016/j.addr.2014.05.013